Synvisc 2 ml

Produkt Beschreibung

Clinical Monograph: Synvisc 2 mL (Hylan G-F 20)

1. Classification and Chemical Overview

• Active Composition: Hylan G-F 20 comprises two high-molecular-weight fluid polymers (Hylan A and Hylan B) produced from hyaluronan (sodium hyaluronate) and chemically cross-linked with divinyl sulfone. Each 2.25 mL glass syringe contains a 2 mL dose (16 mg) of hylan G-F 20.

• Therapeutic Class: Viscosupplement / Intra-articular joint lubricant.

• Regulatory Status: Prescription-only medical device/biological product, administered exclusively by a qualified healthcare professional via intra-articular injection.

2. Mechanism of Action and Pharmacodynamics

• Restoration of Rheologic Homeostasis: Osteoarthritic joint fluid exhibits reduced viscosity and elasticity due to the breakdown of endogenous hyaluronic acid. Synvisc temporarily replaces and replenishes compromised synovial fluid.

• Mechanical Cushioning & Lubrication: The high elasticity and viscosity of the hylan polymers absorb high-frequency compressive loads and protect articular cartilage during movement, reducing pain and improving joint mobility.

3. Approved Clinical Indications and Dosing Scope

• Indication: Treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics (e.g., acetaminophen).

• Dosing Regimen (Standard Synvisc 3-Injection Course):

  • The standard regimen consists of three separate 2 mL injections administered into the affected knee joint space, spaced one week apart.

  • The entire 2 mL volume must be injected into a single knee per session. Strict aseptic technique is mandatory.

4. Pharmacokinetic Profile

• Local Retention & Metabolism: Hylan G-F 20 remains localized primarily within the synovial compartment of the knee joint, where it exerts its mechanical actions.

• Clearance: Over time, the hylan polymers are gradually broken down via systemic metabolic pathways and eliminated primarily through urinary excretion.

5. Physiological Effects and Adverse Event Spectrum

Local injection site reactions are the most frequently reported adverse events, mirroring acute joint inflammation.

Adverse Reaction Profile

• Very Common / Common ($\ge 1/100$ to $<1/10$): Pain at the injection site, localized arthralgia, joint swelling, effusion, warmth, and stiffness.

• Uncommon ($\ge 1/1,000$ to $<1/100$): Muscle cramps, rash, pruritus, nausea, headache, dizziness, chills, and malaise.

• Rare / Severe (<1/1,000): Severe acute inflammatory reactions (pseudosepsis) characterized by marked joint pain, swelling, and effusion requiring arthrocentesis to rule out infection; systemic hypersensitivity reactions (anaphylactoid responses, angioedema, respiratory difficulty).

6. Contraindications, Drug Interactions, and Clinical Precautions

Kontraindikationen

• Known hypersensitivity (allergy) to hyaluronan (sodium hyaluronate) preparations.

• Known avian allergy (sensitivity to chicken proteins, feathers, or egg products).

• Pre-existing infections, skin diseases, or active cutaneous or bacterial infections in the area of the injection site or the target knee joint.

Key Interacting Factors & Warnings

• Quaternary Ammonium Disinfectants: Do not use skin disinfectants containing quaternary ammonium salts for preparation, as hyaluronan can precipitate in their presence.

• Concomitant Joint Disease: Safety and efficacy have not been established in joints other than the knee.

Clinical Precautions and Post-Injection Guidelines

• Effusion Management: Any significant joint effusion (fluid buildup) should be aspirated prior to administering Synvisc.

• Activity Restrictions: As with any invasive joint procedure, patients are strongly advised to avoid strenuous activities (such as high-impact sports, jogging, or tennis) and prolonged weight-bearing activities for approximately 48 hours following the injection.

Weitere Informationen